Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53MVA Vaccine and Pembrolizumab in Advanced Solid Tumors
NCT02432963Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of p53MVA in solid tumor, sponsored by City of Hope. Primary endpoint: Tolerability assessed by CTCAE v4.3 at 20 weeks. Started Dec 2015; status: active, not recruiting.
02
Drugs
p53MVA
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02432963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432963.